SANSURE BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.63 CNY | -0.23% |
|
-1.29% | -9.82% |
| Jun. 12 | Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification | MT |
| Apr. 26 | Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.48 times its estimated earnings per share for the ongoing year.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -9.82% | 1.38B | C | ||
| -4.72% | 12.35B | B+ | ||
| +99.06% | 8.55B | C | ||
| -22.10% | 6.6B | B- | ||
| +8.48% | 5.88B | B | ||
| -22.96% | 3.52B | C | ||
| +6.08% | 2.55B | - | - | |
| +38.04% | 2.39B | C | ||
| -7.04% | 2.33B | B- | ||
| -68.75% | 2.09B | D+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
-
4 months Revenue revision
-
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 688289 Stock
- Ratings Sansure Biotech Inc.
